Novel treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

Novel treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

  Overview

Sound Pharmaceuticals (SPI) is a privately held biopharmaceutical company in Seattle, WA.

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.

Learn more

  News

Sound Pharmaceuticals To Present At The 15th Annual Needham & Company Healthcare Conference

By | Home Page | No Comments

SEATTLE, WA

Sound Pharmaceuticals, a leader in developing novel drug treatments for diseases of the inner ear, announced today that Jonathan Kil, MD, Co-Founder and Chief Executive Officer, has been invited to present at the 15th Annual Needham & Company Healthcare Conference on Wednesday, April 13th, 2016 at 11:20 a.m. EST in New York, NY.

Dr. Kil will share an update on the Company’s milestone achievements from the past year, along with the strategic objectives for its research and development programs for 2016 and beyond. In addition, he will highlight some of the significant market opportunities within the field of otolaryngology, specifically, otology and neurotology.

Needham & Company’s 15th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.

About Sound Pharmaceuticals

Sound Pharmaceuticals, Inc. (SPI) is a pioneer in otologic drug development aimed at treating sensorineural diseases of the inner ear. SPI is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss and tinnitus including ototoxicity and Meniere’s disease. Sensorineural hearing loss is the third largest disease and affects 50 million Americans. SPI is a privately held biotechnology company headquartered in Seattle, WA.

Contact:

Sound Pharmaceuticals

Paul Rickey, CFO

ir@soundpharma.com

www.soundpharma.com

Sound Pharmaceuticals Announces Appointment of Paul Rickey as Chief Financial Officer

By | Home Page | No Comments

Seattle, WA

Sound Pharmaceuticals today announced the appointment of Paul Rickey as Chief Financial Officer (CFO).  Paul Rickey, an experienced life sciences and technology industry executive, joined the company effectiveMarch 1, 2016. Paul will lead the company’s financial and administrative operations.

“Paul brings to our management team proven financial leadership and strategic corporate growth expertise that will be valuable in shaping the future of Sound Pharmaceuticals,” said Dr. Jonathan Kil, CEO. “The Board of Directors joins me in welcoming Paul to his new position as our first CFO and we look forward to his substantial contributions to our future success.”

SPI has multiple ongoing mid-stage clinical trials involving SPI-1005 or SPI-3005 in three different inner ear diseases or neurotologic indications. “The team at Sound Pharma is committed to making a difference in the lives of people suffering from hearing loss and tinnitus. I am honored to join in this mission at this exciting time of execution and growth,” commented Paul Rickey.

Prior to his appointment at Sound Pharmaceuticals, Paul served as Vice President of Finance and Administration of Immune Design Corp., a publicly traded biotechnology company where he helped complete the company’s private offerings, initial public offering, and follow-on financing. In addition, he oversaw the finance, accounting and human resource functions through July of 2015. Before joining Immune Design in 2009, Paul was Corporate Controller of Northstar Neuroscience, a publicly traded medical device company, where he managed the company’s finance and accounting groups following their IPO. Prior to his role at Northstar Neuroscience, he was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Paul started his career at Ernst & Young LLP. He graduated from the University of Washington with a BA and Masters in Professional Accounting and is a Certified Public Accountant.

SPI is a privately held biotech in Seattle, WA developing the first drugs for the prevention and treatment of sensorineural hearing loss and tinnitus.
www.soundpharma.com

Otoprotection

Oral treatments for acute and chronic hearing loss

LEARN MORE

Chemoprotection

Oral combination for the treatment of acute ototoxicity

Learn more

Regeneration

Locally delivered treatments for hearing restoration

Learn more